Syros Pharmaceuticals (NASDAQ:SYRS) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2024 earnings at ($0.73) EPS, Q3 2024 earnings at ($0.74) EPS, Q4 […]
More Stories
AT&T (NYSE:T) Stock Rating Upgraded by Royal Bank of Canada
Royal Bank of Canada upgraded shares of AT&T (NYSE:T – Free Report) from a sector perform rating to an outperform...
Truist Financial Lowers UnitedHealth Group (NYSE:UNH) Price Target to $610.00
UnitedHealth Group (NYSE:UNH – Free Report) had its price objective lowered by Truist Financial from $625.00 to $610.00 in a...
Aptiv (NYSE:APTV) Now Covered by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Aptiv (NYSE:APTV – Free Report) in a research report report published on Monday. The...
BMO Capital Markets Upgrades Capri (NYSE:CPRI) to “Outperform”
BMO Capital Markets upgraded shares of Capri (NYSE:CPRI – Free Report) from a market perform rating to an outperform rating...
Insider Selling: B.P. Marsh & Partners PLC (LON:BPM) Insider Sells £138,937.50 in Stock
B.P. Marsh & Partners PLC (LON:BPM – Get Free Report) insider Francesca Chappell sold 18,750 shares of the stock in...
Bragg Gaming Group (NASDAQ:BRAG) Given New $5.00 Price Target at JMP Securities
Bragg Gaming Group (NASDAQ:BRAG – Free Report) had its price target lowered by JMP Securities from $6.00 to $5.00 in...